Lead Product(s) : ATLX-1282
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : $415.0 million
Deal Type : Licensing Agreement
Alchemab Inks $415M Licensing Deal with Eli Lilly for ATLX-1282 Development
Details : Under the licensing agreement, Alchemab will be taking the programme through early Phase 1 clinical trials of ATLX-1282 after which Lilly will lead all further development and commercialisation.
Product Name : ATLX-1282
Product Type : Antibody
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : ATLX-1282
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : $415.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Cambridge Innovation Capital
Deal Size : $31.0 million
Deal Type : Financing
TRIMTECH Therapeutics Raises $31M Seed Funding
Details : The investment will support development of the Company’s growing pipeline of potent, CNS penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 05, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Cambridge Innovation Capital
Deal Size : $31.0 million
Deal Type : Financing
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : ALS Association
Deal Size : Undisclosed
Deal Type : Funding
Tiziana Awarded ALS Trial Grant by ALS Association for Groundbreaking Study
Details : The grant will fund a clinical trial of two doses of Tiziana’s novel and patented candidate, intranasal TZLS-401 (foralumab), evaluating the safety of disease improvement in ALS.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Undisclosed
November 19, 2024
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : ALS Association
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : Undisclosed
Deal Type : Funding
Lario Therapeutics Awarded $6M Grant from Michael Fox Foundation for Parkinson’s Research
Details : The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of Parkinson’s disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : EPY201
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : UCL Technology Fund
Deal Size : $10.0 million
Deal Type : Financing
EpilepsyGTx Raises $10 Million for CTA-Enabling Nonclinical Package for EPY201
Details : The funds raised will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, for the treatment of focal refractory epilepsy.
Product Name : EPY201
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 24, 2024
Lead Product(s) : EPY201
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : UCL Technology Fund
Deal Size : $10.0 million
Deal Type : Financing
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Actimed Therapeutics Granted FDA Orphan Drug Status for ALS Treatment ACM-002
Details : ACM-002 (S-oxprenolol) has demonstrated slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection in amyotrophic lateral sclerosis (ALS).
Product Name : ACM-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2024
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amphista Shows New Data for Efficacy and CNS Activity of Targeted Protein Degraders
Details : Amphista Therapeutics is developing an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader. It is being evaluated in preclinical studies for neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Novartis Venture Fund
Deal Size : $61.0 million
Deal Type : Series A Financing
Details : The financing will be used to advance a portfolio small-molecule drugs, including a clinical study in patients with Alzheimer's disease for the lead programme.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Novartis Venture Fund
Deal Size : $61.0 million
Deal Type : Series A Financing
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
Details : NI-0401 (foralumab), the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Inapplicable
April 20, 2023
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGT-DTDS
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BGT-DTDS is a neuron-targeted AAV2 investigational gene therapy designed to provide a potentially curative solution to DTDS patients following a one-time intra-brain injection to the substantia nigra and ventral tegmental area.
Product Name : BGT-DTDS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 05, 2023
Lead Product(s) : BGT-DTDS
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable